CN Patent

CN107778293B — 一种改进的德拉沙星的制备方法

Assigned to Lunan Pharmaceutical Group Corp · Expires 2023-06-16 · 3y expired

What this patent protects

本发明属于医药合成领域，具体涉及一种改进的德拉沙星的制备方法。本发明技术方案可以避免4‑氧代苯并吡喃杂质的生成，且后续的取代、环化、对接都可以在同一溶剂中进行，溶剂种类单一，无需繁琐的后处理。使5位氯代物杂质减少，产品的纯度和收率提高。水解反应条件温和，避免了氧化杂质的产生，并摸索了析晶工艺，使固体析晶均匀，解决了料液粘稠易缠反应釜搅拌和结块易堵塞底阀的问题。

USPTO Abstract

本发明属于医药合成领域，具体涉及一种改进的德拉沙星的制备方法。本发明技术方案可以避免4‑氧代苯并吡喃杂质的生成，且后续的取代、环化、对接都可以在同一溶剂中进行，溶剂种类单一，无需繁琐的后处理。使5位氯代物杂质减少，产品的纯度和收率提高。水解反应条件温和，避免了氧化杂质的产生，并摸索了析晶工艺，使固体析晶均匀，解决了料液粘稠易缠反应釜搅拌和结块易堵塞底阀的问题。

Drugs covered by this patent

Patent Metadata

Patent number
CN107778293B
Jurisdiction
CN
Classification
—
Expires
2023-06-16
Drug substance claim
No
Drug product claim
No
Assignee
Lunan Pharmaceutical Group Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.